Biomaterials Translational (eISSN: 2096-112X) is a peer-reviewed, quarterly journal that publishes research at the interface of translational medicine, biomaterials science and engineering, highlighting breakthrough discoveries in basic science and clinical application of biomaterials, as well as other significant findings related to the translation of biomaterials. This journal covers a wide range of contents concerning physical, biological, and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used.

Biomaterials Translational publishes original, high-quality, peer-reviewed papers, including original research articles, reviews, viewpoints and commentaries. This journal is oriented towards materials scientists and chemists who are interested in the clinical applications of novel biomaterials as well as clinicians from all disciplines who are interested in materials sciences.

Original research articles will be considered for publication within, but not limited to, the following domains:

1. Investigation of human biology and pathogenesis of diseases with potential applications of biomaterials in treatment
2. Synthesis, characterization, and biomedical potential of metallic, ceramic, polymeric, composite, and hybrid biomaterials
3. Physical, chemical, biological, pharmaceutical, and toxicological features of biomaterials
4. Drug and gene delivery system design, with a focus on its application to disease conditions
5. Short-term and long-term biocompatibility of biomaterials
6. In vivo disease models and the biology of the host response in the application of novel biomaterials
7. Biomaterials design for modern diagnosis and therapeutic clinical practice (bioimaging, biosensing, biotherapy)
8. Stem cell-biomaterial-based tissue engineering

Biomaterials Translational is sponsored by Chinese Medical Association ​and published by Chinese Medical Multimedia Press.

Copyright
Please note that the copyright of the content published in this journal belongs to the author(s) or the Chinese Medical Association. Authors will retain the copyright of the publication under Open Access, or they will be notified to sign a copyright transfer agreement during manuscript processing, which means that they consent to transfer the copyright in all versions of their article to the Chinese Medical Association. In the latter case, you will not be able to add a license to your work (including any earlier versions of it) unless you have the Chinese Medical Association's permission.

Publishing Model
Hybrid. From January 2025, we (Biomaterials Translational) will endeavor to transfer into a hybrid journal. Authors will have two options to retain copyright for articles published under the open access option or to sign a copyright transfer agreement to transfer the copyright to the Chinese Medical Association which is the sponsor of Biomaterials Translational. More can be reached at: Supports Open Access.